Literature DB >> 18256075

Orthopaedic thromboprophylaxis: limitations of current guidelines.

D Warwick1, O E Dahl, W D Fisher.   

Abstract

Thromboprophylaxis remains a controversial subject. A vast amount of epidemiological and trial data about venous thromboembolism has been published over the past 40 years. These data have been distilled and synthesised into guidelines designed to help the practitioner translate this extensive research into 'evidence-based' advice. Guidelines should, in theory, benefit patient care by ensuring that every patient routinely receives the best prophylaxis; without guidelines, it is argued, patients may fail to receive treatment or be exposed to protocols which are ineffective, dangerous or expensive. Guidelines, however, have not been welcomed or applied universally. In the United States, orthopaedic surgeons have published their concerns about the thromboprophylaxis guidelines prepared by the American College of Chest Physicians. In Britain, controversy persists with many surgeons unconvinced of the risk/benefit, cost/benefit or practicality of thromboprophylaxis. The extended remit of the recent National Institute of Clinical Excellence thromboprophylaxis guidelines has been challenged. The reasons for this disquiet are addressed in this paper and particular emphasis is placed on how clinically-acceptable guidelines could be developed and applied.

Entities:  

Mesh:

Year:  2008        PMID: 18256075     DOI: 10.1302/0301-620X.90B2.20106

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  9 in total

Review 1.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Authors:  Elisabeth Perzborn; Susanne Roehrig; Alexander Straub; Dagmar Kubitza; Frank Misselwitz
Journal:  Nat Rev Drug Discov       Date:  2010-12-17       Impact factor: 84.694

2.  Anticoagulation Bridging Therapy Patterns in Patients Undergoing Total Hip or Total Knee Replacement in a US Health Plan: Real-World Observations and Implications.

Authors:  Onur Baser; Dylan Supina; Nishan Sengupta; Li Wang
Journal:  Am Health Drug Benefits       Date:  2011-07

3.  Risk factors for pulmonary embolism after hip and knee arthroplasty: a population-based study.

Authors:  Stavros G Memtsoudis; Melanie C Besculides; Licia Gaber; Spencer Liu; Alejandro González Della Valle
Journal:  Int Orthop       Date:  2008-10-17       Impact factor: 3.075

4.  The provision of total hip replacement for displaced intracapsular hip fractures.

Authors: 
Journal:  Ann R Coll Surg Engl       Date:  2016-01-07       Impact factor: 1.891

5.  Venous thromboembolism after total knee replacement or total hip replacement: what can be learnt from root-cause analysis?

Authors:  S Benjamin; D Warwick
Journal:  Ann R Coll Surg Engl       Date:  2016-08-11       Impact factor: 1.891

6.  Thromboprophylaxis for deep vein thrombosis and pulmonary embolism after total joint arthroplasty in a low incidence population.

Authors:  Kang-Il Kim; Dong-Geun Kang; Sumit S Khurana; Sang-Hak Lee; Young-Joo Cho; Dae-Kyung Bae
Journal:  Knee Surg Relat Res       Date:  2013-05-29

7.  Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.

Authors:  Richard J Friedman
Journal:  Thrombosis       Date:  2010-09-13

8.  Mechanical prophylaxis after hip fracture: what is the risk of deep vein thrombosis? A retrospective observational study.

Authors:  Majd B Protty; Shridhar Aithal; Ben Hickey; Rebecca Pettit; Antony Johansen
Journal:  BMJ Open       Date:  2015-02-12       Impact factor: 2.692

9.  Venous thromboembolism rates after hip and knee arthroplasty and hip fractures.

Authors:  Viswanath Mula; Sunny Parikh; Sivakolundu Suresh; Alex Bottle; Mark Loeffler; Mahbub Alam
Journal:  BMC Musculoskelet Disord       Date:  2020-02-12       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.